ARWR: Multiple Data Readouts Ahead in 2026
On November 25, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for fiscal year 2026 that ended September 30,...
143 Views
ARWR: REDEMPLO Approved by FDA for the Treatment of FCS
On November 18, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced that the U.S. Food and Drug Administration (FDA) approved REDEMPLO ...
233 Views
ARWR: Signs Collaboration Agreement with Novartis with 200 Million Upfront
On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global license and collaboration agreement with Novartis for ARO-SNCA,...
266 Views
ARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS
On August 7, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2025 that ended June...
467 Views
ARWR: Multiple Value Drivers for Long-Term Growth
On May 12, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2025 that ended March...
169 Views